UA99097C2 - Композиция, содержащая антитела к амилоиду бета 4, имеющие гликозилированный вариабельный участок - Google Patents
Композиция, содержащая антитела к амилоиду бета 4, имеющие гликозилированный вариабельный участокInfo
- Publication number
- UA99097C2 UA99097C2 UAA200808791A UAA200808791A UA99097C2 UA 99097 C2 UA99097 C2 UA 99097C2 UA A200808791 A UAA200808791 A UA A200808791A UA A200808791 A UAA200808791 A UA A200808791A UA 99097 C2 UA99097 C2 UA 99097C2
- Authority
- UA
- Ukraine
- Prior art keywords
- glycosylated
- variable region
- antibody
- antibodies
- asn
- Prior art date
Links
- 102000013455 Amyloid beta-Peptides Human genes 0.000 title 1
- 108010090849 Amyloid beta-Peptides Proteins 0.000 title 1
- 239000000203 mixture Substances 0.000 abstract 5
- 102000001708 Protein Isoforms Human genes 0.000 abstract 3
- 108010029485 Protein Isoforms Proteins 0.000 abstract 3
- 239000000427 antigen Substances 0.000 abstract 2
- 102000036639 antigens Human genes 0.000 abstract 2
- 108091007433 antigens Proteins 0.000 abstract 2
- 150000001508 asparagines Chemical class 0.000 abstract 2
- 238000002360 preparation method Methods 0.000 abstract 2
- 208000037259 Amyloid Plaque Diseases 0.000 abstract 1
- 230000003941 amyloidogenesis Effects 0.000 abstract 1
- 230000015572 biosynthetic process Effects 0.000 abstract 1
- 238000003745 diagnosis Methods 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Mycology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Psychology (AREA)
- Endocrinology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Plant Substances (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP05027090 | 2005-12-12 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UA99097C2 true UA99097C2 (ru) | 2012-07-25 |
Family
ID=37745986
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UAA200808791A UA99097C2 (ru) | 2005-12-12 | 2006-12-11 | Композиция, содержащая антитела к амилоиду бета 4, имеющие гликозилированный вариабельный участок |
Country Status (33)
Families Citing this family (65)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR038568A1 (es) | 2002-02-20 | 2005-01-19 | Hoffmann La Roche | Anticuerpos anti-a beta y su uso |
| DE10303974A1 (de) | 2003-01-31 | 2004-08-05 | Abbott Gmbh & Co. Kg | Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung |
| KR20080090408A (ko) | 2005-11-30 | 2008-10-08 | 아보트 러보러터리즈 | 항-Ａβ 글로불로머 항체, 이의 항원-결합 잔기, 상응하는하이브리도마, 핵산, 벡터, 숙주 세포, 당해 항체의 제조방법, 당해 항체를 포함하는 조성물, 당해 항체의 용도 및당해 항체의 사용 방법 |
| SG10201706600VA (en) | 2005-11-30 | 2017-09-28 | Abbvie Inc | Monoclonal antibodies and uses thereof |
| BRPI0619605B8 (pt) * | 2005-12-12 | 2021-05-25 | Hoffmann La Roche | composições compreendendo moléculas de anticorpos contra amilóide beta4 com glicosilação na região variável, usos das mesmas, método de preparação de uma molécula de anticorpo, e kit |
| US8455626B2 (en) | 2006-11-30 | 2013-06-04 | Abbott Laboratories | Aβ conformer selective anti-aβ globulomer monoclonal antibodies |
| CN101553504A (zh) * | 2006-12-11 | 2009-10-07 | 豪夫迈·罗氏有限公司 | Aβ抗体胃肠外制剂 |
| WO2008104386A2 (en) | 2007-02-27 | 2008-09-04 | Abbott Gmbh & Co. Kg | Method for the treatment of amyloidoses |
| US8048420B2 (en) | 2007-06-12 | 2011-11-01 | Ac Immune S.A. | Monoclonal antibody |
| US8613923B2 (en) | 2007-06-12 | 2013-12-24 | Ac Immune S.A. | Monoclonal antibody |
| EP2167540B1 (en) | 2007-06-29 | 2018-02-14 | F. Hoffmann-La Roche AG | Heavy chain mutant leading to improved immunoglobulin production |
| US9163249B2 (en) | 2007-08-20 | 2015-10-20 | Glaxo Group Limited | Production methods |
| CA2701793C (en) | 2007-10-05 | 2017-04-25 | Genentech, Inc. | Use of anti-amyloid beta antibody in ocular diseases |
| NZ585516A (en) * | 2007-12-21 | 2012-07-27 | Hoffmann La Roche | Anti-cd20 antibody formulation |
| CN102076865B (zh) * | 2008-05-02 | 2016-03-16 | 西雅图基因公司 | 用于制造核心岩藻糖基化降低的抗体和抗体衍生物的方法和组合物 |
| US20140213465A1 (en) * | 2011-12-02 | 2014-07-31 | Plaxgen, Inc. | Plaque array methods and compositions for forming and detecting plaques |
| US20120282654A1 (en) * | 2009-04-29 | 2012-11-08 | Schering Corporation | Antibody purification |
| US20130116413A1 (en) * | 2009-12-29 | 2013-05-09 | Dr. Reddy's Laboratories, Inc. | Purification of proteins |
| WO2011107507A1 (en) | 2010-03-03 | 2011-09-09 | Boehringer Ingelheim International Gmbh | Biparatopic abeta binding polypeptides |
| EP2558494B1 (en) | 2010-04-15 | 2018-05-23 | AbbVie Inc. | Amyloid-beta binding proteins |
| CN103179981B (zh) | 2010-07-30 | 2017-02-08 | Ac免疫有限公司 | 安全和功能性的人源化抗β‑淀粉样蛋白抗体 |
| US9062101B2 (en) | 2010-08-14 | 2015-06-23 | AbbVie Deutschland GmbH & Co. KG | Amyloid-beta binding proteins |
| US20140302532A1 (en) | 2011-04-12 | 2014-10-09 | Quanterix Corporation | Methods of determining a treatment protocol for and/or a prognosis of a patient's recovery from a brain injury |
| SG11201401360XA (en) * | 2011-10-25 | 2014-05-29 | Onclave Therapeutics Ltd | Antibody formulations and methods |
| NZ626955A (en) | 2012-03-08 | 2016-01-29 | Hoffmann La Roche | Abeta antibody formulation |
| CA2879496C (en) * | 2012-08-29 | 2024-01-09 | F. Hoffmann-La Roche Ag | Blood brain barrier shuttle |
| CN102998454A (zh) * | 2012-12-11 | 2013-03-27 | 华中师范大学 | 一种检测生物体内邻苯二甲酸二丁酯相对含量的方法 |
| US9587022B2 (en) | 2012-12-18 | 2017-03-07 | The Rockefeller University | Glycan-modified anti-CD4 antibody with improved HIV-1 neutralizing activity |
| CN105228650B (zh) | 2012-12-18 | 2018-11-16 | 美国洛克菲勒大学 | 用于hiv预防和治疗的聚糖修饰的抗-cd4抗体 |
| BR112015019341A2 (pt) | 2013-02-13 | 2017-08-22 | Lab Francais Du Fractionnement | Anticorpo anti-tnf-alfa, composição que compreende o anticorpo, método para produzir uma população de anticorpos, células epiteliais da glândula mamária, mamífero não humano transgênico, e, composição de anticorpo anti-tnf monoclonal |
| JP6169885B2 (ja) | 2013-05-07 | 2017-07-26 | 株式会社日立製作所 | 精製装置及び精製方法 |
| CN105722532A (zh) | 2013-09-13 | 2016-06-29 | 豪夫迈·罗氏有限公司 | 包含纯化的重组多肽的方法和组合物 |
| BR112016004437A2 (pt) | 2013-09-13 | 2017-10-17 | Genentech Inc | métodos de imunoteste e de seleção de linhagem de células, anticorpos e kit |
| EP3072506B1 (en) | 2013-11-22 | 2022-04-20 | The University of Tokyo | Carrier for drug delivery and conjugate, composition containing same, and method for administering same |
| WO2015155694A1 (en) | 2014-04-08 | 2015-10-15 | Prothena Biosciences Limited | Blood-brain barrier shuttles containing antibodies recognizing alpha-synuclein |
| WO2015165961A1 (en) | 2014-04-29 | 2015-11-05 | Affiris Ag | Treatment and prevention of alzheimer's disease (ad) |
| IL302486A (en) | 2015-06-24 | 2023-06-01 | Hoffmann La Roche | Antibodies against the transnephrine receptor with adapted affinity |
| FR3038517B1 (fr) | 2015-07-06 | 2020-02-28 | Laboratoire Francais Du Fractionnement Et Des Biotechnologies | Utilisation de fragments fc modifies en immunotherapie |
| PL3337812T3 (pl) * | 2015-08-21 | 2021-10-11 | F. Hoffmann-La Roche Ag | Sposób zmniejszenia zawartości białek komórki gospodarza w chromatografii powinowactwa |
| JP6657392B2 (ja) | 2015-10-02 | 2020-03-04 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | 二重特異性抗ヒトｃｄ２０／ヒトトランスフェリン受容体抗体及び使用方法 |
| AR106189A1 (es) | 2015-10-02 | 2017-12-20 | Hoffmann La Roche | ANTICUERPOS BIESPECÍFICOS CONTRA EL A-b HUMANO Y EL RECEPTOR DE TRANSFERRINA HUMANO Y MÉTODOS DE USO |
| EP3155958B1 (en) * | 2015-10-16 | 2021-11-17 | Roche Diabetes Care GmbH | A method for operating a system and a system |
| CN108350051A (zh) | 2015-11-09 | 2018-07-31 | 英属哥伦比亚大学 | 淀粉样蛋白β中的N-末端表位及其构象选择性抗体 |
| AU2016354688B2 (en) | 2015-11-09 | 2021-12-16 | The University Of British Columbia | Epitopes in Amyloid beta mid-region and conformationally-selective antibodies thereto |
| CA3004498A1 (en) | 2015-11-09 | 2017-05-18 | Neil R. Cashman | Amyloid beta epitopes and antibodies thereto |
| US10792477B2 (en) * | 2016-02-08 | 2020-10-06 | Orbusneich Medical Pte. Ltd. | Drug eluting balloon |
| EP3427183A1 (en) * | 2016-03-10 | 2019-01-16 | Genomic Vision | Method of curvilinear signal detection and analysis and associated platform |
| US11326182B2 (en) | 2016-04-29 | 2022-05-10 | Voyager Therapeutics, Inc. | Compositions for the treatment of disease |
| TWI735600B (zh) | 2016-07-01 | 2021-08-11 | 美商美國禮來大藥廠 | 抗－N3pGlu類澱粉β肽抗體及其用途 |
| EP3484919A4 (en) | 2016-07-18 | 2020-03-04 | The University of British Columbia | ANTI-BETA-AMYLOID ANTIBODIES |
| US20180125920A1 (en) | 2016-11-09 | 2018-05-10 | The University Of British Columbia | Methods for preventing and treating A-beta oligomer-associated and/or -induced diseases and conditions |
| AU2018277333B2 (en) * | 2017-05-30 | 2021-09-16 | Morinaga Milk Industry Co., Ltd. | Composition for improving brain function |
| US12286469B2 (en) | 2017-07-18 | 2025-04-29 | The University Of British Columbia | Humanized antibodies binding to amyloid-beta (A-beta) |
| JP7330164B2 (ja) | 2017-07-18 | 2023-08-21 | ザ・ユニバーシティ・オブ・ブリティッシュ・コロンビア | アミロイドベータに対する抗体 |
| CN108048477A (zh) * | 2017-12-15 | 2018-05-18 | 南京理工大学 | 基于大肠杆菌表达系统的制备多肽的方法 |
| EP3778875A1 (en) | 2019-08-14 | 2021-02-17 | MaxiVax SA | Immortalized myoblast cell lines and uses thereof |
| JP2023535024A (ja) | 2020-07-23 | 2023-08-15 | オター プロシーナ リミテッド | 抗ａベータ抗体 |
| KR20230109674A (ko) * | 2020-11-16 | 2023-07-20 | 에프. 호프만-라 로슈 아게 | Fab 고 만노스 당형 |
| TW202300517A (zh) | 2021-03-12 | 2023-01-01 | 美商美國禮來大藥廠 | 抗類澱粉β抗體及其用途 |
| WO2022251048A1 (en) | 2021-05-24 | 2022-12-01 | Eli Lilly And Company | Anti-amyloid beta antibodies and uses thereof |
| CN114591429B (zh) * | 2022-05-07 | 2022-08-09 | 北京第一生物化学药业有限公司 | 结合β-淀粉样蛋白的抗体及其用途 |
| TW202434629A (zh) | 2023-01-26 | 2024-09-01 | 愛爾蘭商歐薩爾普羅席納有限公司 | 以抗類澱粉β (ABETA)抗體治療神經病症之方法 |
| WO2025032070A1 (en) | 2023-08-09 | 2025-02-13 | F. Hoffmann-La Roche Ag | Anti-a-beta protein antibodies, methods and uses thereof |
| WO2025032069A1 (en) | 2023-08-09 | 2025-02-13 | F. Hoffmann-La Roche Ag | Mono and multispecific anti-trem2 antibodies, methods and uses thereof |
| CN117783359B (zh) * | 2023-12-28 | 2024-12-31 | 中国计量科学研究院 | 一种基于串联质谱的转基因蛋白多靶同检方法 |
Family Cites Families (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4666829A (en) | 1985-05-15 | 1987-05-19 | University Of California | Polypeptide marker for Alzheimer's disease and its use for diagnosis |
| GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
| US5811310A (en) | 1986-09-30 | 1998-09-22 | Albert Einstein College Of Medicine Of Yeshiva Univ. | The Alz-50 monoclonal antibody and diagnostic assay for alzheimer's disease |
| GB8717430D0 (en) | 1987-07-23 | 1987-08-26 | Celltech Ltd | Recombinant dna product |
| CA1339014C (en) | 1987-10-08 | 1997-03-25 | Ronald E. Majocha | Antibodies to a4 amyloid peptide |
| JP2780507B2 (ja) | 1991-03-29 | 1998-07-30 | 松下電器産業株式会社 | 内燃機関用フィルタ再生装置 |
| US5955317A (en) | 1993-01-25 | 1999-09-21 | Takeda Chemical Industries, Ltd. | Antibodies to β-amyloids or their derivatives and use thereof |
| WO1994017197A1 (fr) | 1993-01-25 | 1994-08-04 | Takeda Chemical Industries, Ltd. | ANTICORPS DIRIGE CONTRE LE β-AMYLOIDE OU UN DERIVE DE CE DERNIER ET SON UTILISATION |
| US5443953A (en) * | 1993-12-08 | 1995-08-22 | Immunomedics, Inc. | Preparation and use of immunoconjugates |
| GB9416007D0 (en) * | 1994-08-08 | 1994-09-28 | Erba Carlo Spa | Anthracyclinone derivatives |
| US5688651A (en) | 1994-12-16 | 1997-11-18 | Ramot University Authority For Applied Research And Development Ltd. | Prevention of protein aggregation |
| AU5976996A (en) * | 1995-06-06 | 1996-12-24 | Stemcell Therapeutics L.L.C. | Glycoprotein gp105 on bl3 hematopoietic stem cells |
| CA2229043C (en) | 1995-08-18 | 2016-06-07 | Morphosys Gesellschaft Fur Proteinoptimierung Mbh | Protein/(poly)peptide libraries |
| US7964192B1 (en) | 1997-12-02 | 2011-06-21 | Janssen Alzheimer Immunotherapy | Prevention and treatment of amyloidgenic disease |
| TWI239847B (en) | 1997-12-02 | 2005-09-21 | Elan Pharm Inc | N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease |
| US6660843B1 (en) | 1998-10-23 | 2003-12-09 | Amgen Inc. | Modified peptides as therapeutic agents |
| AU781292B2 (en) * | 1999-03-04 | 2005-05-12 | Praecis Pharmaceuticals Incorporated | Modulators of beta-amyloid peptide aggregation comprising D-amino acids |
| DK1409654T3 (da) | 1999-06-16 | 2008-12-08 | Boston Biomedical Res Inst | Immunologisk styring af beta-amyloid-niveauer in vivo |
| AU6722300A (en) | 1999-08-31 | 2001-03-26 | Ramot University Authority For Applied Research And Industrial Development Ltd. | Peptides and substances, methods and devices using same for diagnosing and treating neurodegenerative disorders |
| AU784312B2 (en) | 1999-11-29 | 2006-03-09 | Bellus Health (International) Limited | Vaccine for the prevention and treatment of alzheimer's and amyloid related diseases |
| US20020094335A1 (en) | 1999-11-29 | 2002-07-18 | Robert Chalifour | Vaccine for the prevention and treatment of alzheimer's and amyloid related diseases |
| EP1125905A1 (en) | 2000-02-16 | 2001-08-22 | Pepscan Systems B.V. | Segment synthesis |
| KR100767146B1 (ko) | 2000-02-24 | 2007-10-15 | 워싱톤 유니버시티 | Ａβ 펩티드를 격리시키는 인간화 항체 |
| CA2313828A1 (en) | 2000-08-01 | 2002-02-01 | Institut De Recherches Cliniques De Montreal/Ircm | Post-translational processing of .beta.-secretase (bace): the pro-and transmembrane/cytosolic domains affect its cellular activity and amyloid a.beta. production |
| PE20020574A1 (es) | 2000-12-06 | 2002-07-02 | Wyeth Corp | Anticuerpos humanizados que reconocen el peptido amiloideo beta |
| CA2436789A1 (en) | 2000-12-19 | 2002-08-22 | Palatin Technologies, Inc. | Identification of target-specific folding sites in peptides and proteins |
| ES2312569T3 (es) | 2001-04-30 | 2009-03-01 | Eli Lilly And Company | Anticuerpos humanizados. |
| ATE420114T1 (de) | 2001-04-30 | 2009-01-15 | Lilly Co Eli | Humanisierte antikörper die das beta-amyloid peptid erkennen& x9; |
| ES2391905T3 (es) * | 2001-08-17 | 2012-11-30 | Washington University | Método de ensayo para la enfermedad de alzheimer |
| US20040192898A1 (en) * | 2001-08-17 | 2004-09-30 | Jia Audrey Yunhua | Anti-abeta antibodies |
| AR038568A1 (es) * | 2002-02-20 | 2005-01-19 | Hoffmann La Roche | Anticuerpos anti-a beta y su uso |
| MY139983A (en) | 2002-03-12 | 2009-11-30 | Janssen Alzheimer Immunotherap | Humanized antibodies that recognize beta amyloid peptide |
| MXPA05003621A (es) | 2002-10-09 | 2005-10-19 | Rinat Neuroscience Corp | Metodos de tratamiento de la enfermedad de alzheimer usando anticuerpos dirigidos contra el peptido beta amiloide y composiciones de los mismos. |
| DE10303974A1 (de) * | 2003-01-31 | 2004-08-05 | Abbott Gmbh & Co. Kg | Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung |
| BRPI0619605B8 (pt) * | 2005-12-12 | 2021-05-25 | Hoffmann La Roche | composições compreendendo moléculas de anticorpos contra amilóide beta4 com glicosilação na região variável, usos das mesmas, método de preparação de uma molécula de anticorpo, e kit |
| CN101553504A (zh) * | 2006-12-11 | 2009-10-07 | 豪夫迈·罗氏有限公司 | Aβ抗体胃肠外制剂 |
-
2006
- 2006-12-11 BR BRPI0619605A patent/BRPI0619605B8/pt active IP Right Grant
- 2006-12-11 US US12/086,309 patent/US8906370B2/en active Active
- 2006-12-11 NZ NZ568241A patent/NZ568241A/en unknown
- 2006-12-11 EP EP06829502A patent/EP1960428B1/en active Active
- 2006-12-11 EP EP11169488A patent/EP2377886A1/en not_active Withdrawn
- 2006-12-11 KR KR1020087012289A patent/KR20080077132A/ko not_active Ceased
- 2006-12-11 SI SI200631096T patent/SI1960428T1/sl unknown
- 2006-12-11 PE PE2010000354A patent/PE20100684A1/es not_active Application Discontinuation
- 2006-12-11 PE PE2010000560A patent/PE20100748A1/es active IP Right Grant
- 2006-12-11 WO PCT/EP2006/011914 patent/WO2007068429A1/en not_active Ceased
- 2006-12-11 CN CN2006800463079A patent/CN101351476B/zh active Active
- 2006-12-11 PE PE2006001587A patent/PE20071002A1/es not_active Application Discontinuation
- 2006-12-11 RU RU2008128138/10A patent/RU2438706C2/ru active
- 2006-12-11 AU AU2006326301A patent/AU2006326301B2/en active Active
- 2006-12-11 CN CN201210137369.8A patent/CN102659943B/zh active Active
- 2006-12-11 AT AT06829502T patent/ATE517923T1/de active
- 2006-12-11 JO JO2006444A patent/JO2824B1/en active
- 2006-12-11 PL PL06829502T patent/PL1960428T3/pl unknown
- 2006-12-11 MY MYPI20081349A patent/MY155286A/en unknown
- 2006-12-11 DO DO2006000278A patent/DOP2006000278A/es unknown
- 2006-12-11 PT PT06829502T patent/PT1960428E/pt unknown
- 2006-12-11 TW TW095146304A patent/TWI382990B/zh active
- 2006-12-11 DK DK06829502.1T patent/DK1960428T3/da active
- 2006-12-11 KR KR1020127010552A patent/KR101401159B1/ko active Active
- 2006-12-11 UA UAA200808791A patent/UA99097C2/ru unknown
- 2006-12-11 RS RS20110401A patent/RS52004B/sr unknown
- 2006-12-11 AR ARP060105433A patent/AR057233A1/es unknown
- 2006-12-11 CA CA2632828A patent/CA2632828C/en active Active
- 2006-12-11 NO NO20082874A patent/NO346105B1/no unknown
- 2006-12-11 JP JP2008543748A patent/JP5145241B2/ja active Active
- 2006-12-11 ES ES06829502T patent/ES2368591T3/es active Active
- 2006-12-11 UY UY30003A patent/UY30003A1/es unknown
-
2008
- 2008-04-27 IL IL191004A patent/IL191004A/en active IP Right Grant
- 2008-05-20 CR CR10000A patent/CR10000A/es unknown
- 2008-06-09 MA MA31014A patent/MA30038B1/fr unknown
- 2008-06-10 EC EC2008008524A patent/ECSP088524A/es unknown
- 2008-06-10 ZA ZA200805038A patent/ZA200805038B/xx unknown
-
2011
- 2011-09-16 CY CY20111100899T patent/CY1114783T1/el unknown
-
2014
- 2014-11-07 US US14/536,262 patent/US9272031B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| UA99097C2 (ru) | Композиция, содержащая антитела к амилоиду бета 4, имеющие гликозилированный вариабельный участок | |
| MX2009004399A (es) | Polipeptidos con propiedades antiinflamatorias aumentadas y citotoxicas reducidas y metodos relacionados. | |
| KR102323301B1 (ko) | Cys 연결된 항체-약물 접합체의 정제 방법 | |
| NO20083805L (no) | Anvendelse av et antistoff som binder Aβ-peptidsekvenser | |
| PT1639011E (pt) | Anticorpos (dab) de domínio único peguilados | |
| HUS1600019I1 (hu) | Polipeptideket tartalmazó készítmények | |
| WO2006094192A3 (en) | Humanized l243 antibodies | |
| WO2003070760A3 (en) | Anti-amyloid beta antibodies and their use | |
| DE60328108D1 (de) | Iscom-zubereitung und ihre verwendung | |
| ATE425181T1 (de) | Therapeutische zusammensetzungen aus antikorper und antisens nukleinsäuren gegen serrate | |
| ATE419009T1 (de) | Methoden und zusammensetzungen bestehend aus glykoprotein-glykoformen | |
| UA102667C2 (uk) | Людське нейтралізуюче антитіло проти в7rp1 | |
| WO2005016455A3 (en) | Antibodies against factor viii with modified glycosylation in the variable region | |
| DE60236536D1 (de) | Modifizierter anti-tnf antikörper | |
| WO2003083485A3 (en) | Protein for use in hypoxia related conditions | |
| MA34135B1 (fr) | Protéines de liaison à un antigène spécifiques pour un composant p de substance amyloïde sérique | |
| BR0109846A (pt) | Uso de uma composição que compreende um anticorpo ou um fragmento de ligação de antìgeno deste, e conjunto | |
| WO2008100563A3 (en) | Compositions and methods for diagnosing and treating cancer | |
| WO2005048822A3 (en) | Antibodies and/or conjugates thereof which bind to the amino terminal fragment of urokinase, compositions and uses thereof | |
| WO2002098454A3 (en) | Recombinant molecules with reduced immunogenicity, methods and intermediates for obtaining them and their use in pharmaceutical compositions and diagnostic tools | |
| TH90393B (th) | แอนติบอดีไกลโคซิลเลชันในบริเวณผันแปร | |
| GB0510627D0 (en) | Polypeptides | |
| WO2000017363A3 (en) | Interleukin-1 like molecule: interleukin-1-zeta; nucleic acids, polypeptides, antibodies, their uses | |
| WO2025072888A3 (en) | Anti-sars-cov-2 spike (s) antibodies and their use in treating covid-19 | |
| MA47671A (fr) | Molécules de liaison d'antigène comprenant un trimère de ligand de la famille tnf |